Catalyst Pharmaceuticals (CPRX) News Today

Catalyst Pharmaceuticals, Inc. (CPRX) — Investors are reacting to a takeover bid and related legal/analyst developments. The headline M&A offer from Angelini at $31.50/share (a ~28% premium to recent VWAP) is the primary upward catalyst, while analyst action and shareholder-lawyer inquiries are creating short-term uncertainty.

• Positive Sentiment: Angelini Pharma agreed to acquire Catalyst for $31.50 per share in cash (~$4.1B total), unanimously approved by both boards and expected to close in Q3 2026 — this cash offer at a significant premium is the main driver lifting CPRX share value. Angelini press release
• Positive Sentiment: Catalyst announced a settlement with Hetero Labs resolving FIRDAPSE patent litigation and licensing a generic not to enter the U.S. before January 2035 (pending FDA approval), which preserves exclusivity and revenue visibility for the drug for years. Settlement release
• Neutral Sentiment: Stephens reiterated an "Equal Weight" view on CPRX in a note (coverage maintained but not bullish), which is informational but not a major counter to the buyout premium. Coverage note
• Neutral Sentiment: Pre-earnings commentary (Zacks) examining Q1 metrics provides context for fundamentals but is secondary to the takeover news in driving intraday moves. Zacks preview
• Negative Sentiment: Stephens (reported by market outlets) also reduced its stance from "Overweight" to "Equal Weight" in related notes — an analyst downgrade can cap upside for shares not yet exchanged into the deal. Benzinga report
• Negative Sentiment: Two investor-law firms (Ademi LLP and Halper Sadeh LLC) have launched investigations asserting the $31.50 offer may not be fair to public shareholders; such litigation or proxy/legal scrutiny can delay closing, increase transaction risk, or pressure the stock. Ademi alert Halper Sadeh alert

Bottom line for investors: the bid at $31.50 is the dominant positive driver (cash premium + closing timeline). Watch for legal/FTC/DOJ review of the patent settlement and any shareholder litigation or pushback that could delay or alter the deal terms — those are the main near-term downside risks that could weaken the share reaction despite the buyout price.